{"id":3468,"date":"2024-12-02T10:00:17","date_gmt":"2024-12-02T09:00:17","guid":{"rendered":"https:\/\/www.fondazionebonadonna.eu\/?p=3468"},"modified":"2024-11-11T14:23:23","modified_gmt":"2024-11-11T13:23:23","slug":"anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma","status":"publish","type":"post","link":"https:\/\/www.fondazionebonadonna.eu\/en\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\/","title":{"rendered":"Anti-PD-L1 plus targeted therapy in anaplastic thyroid carcinoma"},"content":{"rendered":"<div class=\"wpb-content-wrapper\"><p>[vc_row][vc_column][vc_custom_heading text=&#8221;In a new nonrandomized clinical trial atezolizumab combined with targeted therapy increases overall survival in patients with anaplastic thyroid carcinoma&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;1\/2&#8243;][vc_column_text]A phase 2 nonrandomized clinical trial, <a href=\"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2825251\" target=\"_blank\" rel=\"noopener\">recently published on JAMA Oncology<\/a>, shows promising results with the anti-PD-L1 atezolizumab combined with genetically matched targeted therapy in patients with anaplastic thyroid carcinoma, with or without BRAF mutations.<\/p>\n<p>Authors enrolled 42 patients in three different targeted therapy cohorts: patients with mutated <em>BRAF<\/em> V600E tumors received vemurafenib\/cobimetinib plus atezolizumab (cohort 1); those with mutated <em>RAS (NRAS, KRAS, or HRAS)<\/em> or <em>NF1\/2<\/em> tumors received cobimetinib plus atezolizumab (cohort 2); patients without any of these variants were assigned to receive bevacizumab plus atezolizumab (cohort 3). The median overall survival across the three cohorts was 19 months, ranging from 43 months in patients from cohort 1 to 6.21 months in cohort 3; the progression-free survival was of 13.9 months in cohort1, 4.8 months in cohort 2 and 1.3 months in cohort 3. \u00abPrimary resistance to single-agent targeted therapy is common in anaplastic thyroid carcinoma and despite success with BRAF and MEK inhibitors, specifically for BRAF mutations, inevitably resistance occurs. Recognizing that these tumors have oncogenic driver mutations, but that invariably develop resistance to targeted therapy alone, we designed this novel trial combining atezolizumab with targeted therapy, hypothesizing that this approach would result in a significantly longer median overall survival\u00bb, authors say. \u00abResults show that the genetically-matched targeted therapy plus immunotherapy combination strategy across cohorts 1 to 3 resulted in an overall survival of 19 months\u2014to our knowledge the longest overall survival reported to date in an anaplastic thyroid carcinoma clinical trial. Mutation-directed targeted therapy in combination with PD-L1 inhibitor immunotherapy is a promising strategy to extend overall survival in patients with anaplastic thyroid carcinoma. Further studies in patients with non\u2013BRAF-mutated anaplastic thyroid carcinoma, using better targeted agents, are needed\u00bb, authors conclude.[\/vc_column_text][\/vc_column][vc_column width=&#8221;1\/2&#8243;][vc_single_image image=&#8221;1802&#8243; img_size=&#8221;large&#8221;][\/vc_column][\/vc_row]<\/p>\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_custom_heading text=&#8221;In a new nonrandomized clinical trial atezolizumab combined with targeted therapy increases overall survival in patients with anaplastic thyroid carcinoma&#8221; font_container=&#8221;tag:h3|text_align:left&#8221; use_theme_fonts=&#8221;yes&#8221;][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;1\/2&#8243;][vc_column_text]A phase 2<span class=\"excerpt-hellip\"> [\u2026]<\/span><\/p>\n","protected":false},"author":2,"featured_media":1803,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[39,21],"tags":[],"class_list":["post-3468","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-events","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Anti-PD-L1 plus targeted therapy in anaplastic thyroid carcinoma - Fondazione Gianni Bonadonna<\/title>\n<meta name=\"description\" content=\"In a new nonrandomized clinical trial atezolizumab combined with targeted therapy increases overall survival in patients with anaplastic thyroid carcinoma\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.fondazionebonadonna.eu\/en\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anti-PD-L1 plus targeted therapy in anaplastic thyroid carcinoma - Fondazione Gianni Bonadonna\" \/>\n<meta property=\"og:description\" content=\"In a new nonrandomized clinical trial atezolizumab combined with targeted therapy increases overall survival in patients with anaplastic thyroid carcinoma\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.fondazionebonadonna.eu\/en\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\/\" \/>\n<meta property=\"og:site_name\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-02T09:00:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/01\/AdobeStock_259168782.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2500\" \/>\n\t<meta property=\"og:image:height\" content=\"1500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fondazione Gianni Bonadonna\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fondazione Gianni Bonadonna\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\\\/\"},\"author\":{\"name\":\"Fondazione Gianni Bonadonna\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"headline\":\"Anti-PD-L1 plus targeted therapy in anaplastic thyroid carcinoma\",\"datePublished\":\"2024-12-02T09:00:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\\\/\"},\"wordCount\":348,\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/AdobeStock_259168782.jpg\",\"articleSection\":[\"Events\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\\\/\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\\\/\",\"name\":\"Anti-PD-L1 plus targeted therapy in anaplastic thyroid carcinoma - Fondazione Gianni Bonadonna\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/AdobeStock_259168782.jpg\",\"datePublished\":\"2024-12-02T09:00:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\"},\"description\":\"In a new nonrandomized clinical trial atezolizumab combined with targeted therapy increases overall survival in patients with anaplastic thyroid carcinoma\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/AdobeStock_259168782.jpg\",\"contentUrl\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/wp-content\\\/uploads\\\/2022\\\/01\\\/AdobeStock_259168782.jpg\",\"width\":2500,\"height\":1500},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anti-PD-L1 plus targeted therapy in anaplastic thyroid carcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/\",\"name\":\"Fondazione Gianni Bonadonna\",\"description\":\"Fondazione Gianni Bonadonna\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/#\\\/schema\\\/person\\\/ad83ff3574293b8bca712a59db515146\",\"name\":\"Fondazione Gianni Bonadonna\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g\",\"caption\":\"Fondazione Gianni Bonadonna\"},\"url\":\"https:\\\/\\\/www.fondazionebonadonna.eu\\\/en\\\/author\\\/fgb\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anti-PD-L1 plus targeted therapy in anaplastic thyroid carcinoma - Fondazione Gianni Bonadonna","description":"In a new nonrandomized clinical trial atezolizumab combined with targeted therapy increases overall survival in patients with anaplastic thyroid carcinoma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.fondazionebonadonna.eu\/en\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\/","og_locale":"en_US","og_type":"article","og_title":"Anti-PD-L1 plus targeted therapy in anaplastic thyroid carcinoma - Fondazione Gianni Bonadonna","og_description":"In a new nonrandomized clinical trial atezolizumab combined with targeted therapy increases overall survival in patients with anaplastic thyroid carcinoma","og_url":"https:\/\/www.fondazionebonadonna.eu\/en\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\/","og_site_name":"Fondazione Gianni Bonadonna","article_published_time":"2024-12-02T09:00:17+00:00","og_image":[{"width":2500,"height":1500,"url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/01\/AdobeStock_259168782.jpg","type":"image\/jpeg"}],"author":"Fondazione Gianni Bonadonna","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fondazione Gianni Bonadonna","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\/#article","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\/"},"author":{"name":"Fondazione Gianni Bonadonna","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"headline":"Anti-PD-L1 plus targeted therapy in anaplastic thyroid carcinoma","datePublished":"2024-12-02T09:00:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\/"},"wordCount":348,"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/01\/AdobeStock_259168782.jpg","articleSection":["Events"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\/","url":"https:\/\/www.fondazionebonadonna.eu\/en\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\/","name":"Anti-PD-L1 plus targeted therapy in anaplastic thyroid carcinoma - Fondazione Gianni Bonadonna","isPartOf":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\/#primaryimage"},"image":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\/#primaryimage"},"thumbnailUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/01\/AdobeStock_259168782.jpg","datePublished":"2024-12-02T09:00:17+00:00","author":{"@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146"},"description":"In a new nonrandomized clinical trial atezolizumab combined with targeted therapy increases overall survival in patients with anaplastic thyroid carcinoma","breadcrumb":{"@id":"https:\/\/www.fondazionebonadonna.eu\/en\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.fondazionebonadonna.eu\/en\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\/#primaryimage","url":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/01\/AdobeStock_259168782.jpg","contentUrl":"https:\/\/www.fondazionebonadonna.eu\/wp-content\/uploads\/2022\/01\/AdobeStock_259168782.jpg","width":2500,"height":1500},{"@type":"BreadcrumbList","@id":"https:\/\/www.fondazionebonadonna.eu\/en\/anti-pd-l1-plus-targeted-therapy-in-anaplastic-thyroid-carcinoma\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.fondazionebonadonna.eu\/en\/"},{"@type":"ListItem","position":2,"name":"Anti-PD-L1 plus targeted therapy in anaplastic thyroid carcinoma"}]},{"@type":"WebSite","@id":"https:\/\/www.fondazionebonadonna.eu\/#website","url":"https:\/\/www.fondazionebonadonna.eu\/","name":"Fondazione Gianni Bonadonna","description":"Fondazione Gianni Bonadonna","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.fondazionebonadonna.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.fondazionebonadonna.eu\/#\/schema\/person\/ad83ff3574293b8bca712a59db515146","name":"Fondazione Gianni Bonadonna","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/9744a5b02beb7a6cb027c368f8a9ba8a800a8ff603b5fad54fcf92b808333d81?s=96&d=mm&r=g","caption":"Fondazione Gianni Bonadonna"},"url":"https:\/\/www.fondazionebonadonna.eu\/en\/author\/fgb\/"}]}},"_links":{"self":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/3468","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/comments?post=3468"}],"version-history":[{"count":0,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/posts\/3468\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media\/1803"}],"wp:attachment":[{"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/media?parent=3468"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/categories?post=3468"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fondazionebonadonna.eu\/en\/wp-json\/wp\/v2\/tags?post=3468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}